Page 1869 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

30. Gault MH, Longerich LL, Harnett JD, Weslowski C. Predicting 50. Watkins PB. Drug metabolism by cytochromes p450 in the liver
glomerular function from adjusted creatinine. Nephron. and small bowel. Gastroenterol Clin North Am. 1992;21:511.
1992;62:249. 51. Spinler SA, Cheng JWM, Kindwall KE, Charland SL. Possible
31. Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of inhibition of hepatic metabolism of quinidine by erythromycin.
creatinine clearance estimates in the assessment of renal func- Clin Pharmacol Ther. 1995;57:89.
tion. Clin Pharmacol Ther. 1990;48:503. 52. Nelson DR. Cytochrome P450 Homepage. Hum Genomics.
32. Lindeman RD. Assessment of renal function in the old: special 2009;4(1):59-65.
considerations. Clin Lab Med. 1993;13:269. 53. Danielson PB. The cytochrome P450 superfamily: biochem-
33. Ducharme MP, Smythe M, Strohs G. Drug-induced altera- istry, evolution and drug metabolism in humans. Curr Drug
tions in serum creatinine concentrations. Ann Pharmacother. Metab. 2002;3:561-597.
1993;27:622. 54. Alvares AP, Pratt WB. Pathways of drug metabolism. In: Pratt
34. Stevens LA. Measured GFR as a confirmatory test for estimated WB, Taylor P, eds. Principles of Drug Action. 3rd ed. New York:
GFR. J AM Soc Nephrol. 2009;20:2305-2313. Churchill Livingstone; 1990:40.
35. Martin C, Alaya M, Bras J, et al. Assessment of creatinine clear- 55. OMalley K, Crooks J, Duke E, Stevenson IH. Effect of age and
ance in intensive care patients. Crit Care Med. 1990;18:1224. sex on human drug metabolism. Br Med J. 1971;3:607.
36. Robert S, Zarowitz BJ. Is there a reliable index of glomerular filtra- 56. Masimirembwa CM, Beke M, Hasler JA, et al. Low CYP 1A2
tion rate in critically ill patients? Ann Pharmacother. 1991;25:169. activity in rural Shona children of Zimbabwe. Clin Pharmacol
37. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of Ther. 1995;57:25.
creatinine clearance estimates in critically ill patients. Crit Care 57. May DG, Porter GR, Branch RA. Frequency distribution of
Med. 1993;21:1487. dapsone N-hydroxylase, a putative probe for P4503A4 activity,
38. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method in a white population. Clin Pharmacol Ther. 1994;55:492.
to estimate glomerular filtration rate from serum creatinine: a 58. Lown K, Kolars J, Turgeon K, et al. The erythromycin breath
new prediction equation. Modification of Diet in Renal Disease test selectively measures P450IIIA in patients with severe liver
Study Group. Ann Intern Med. 1999;130:461. disease. Clin Pharmacol Ther. 1992;51:229.
39. Stevens LA comparative performance of the CKD epidemiology 59. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin
collaboration (CKD_EPI) and the modification of diet in renal breath test predicts the clearance of midazolam. Clin Pharmacol
disease (MDRD) Study equations for estimating GFR above Ther. 1995;57:16.
60ml/min. Am J Kidney Dis. 2010;56:486. 60. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender
40. Zarowitz BJ, Robert S, Peterson EL. Prediction of glomerular on the activity of human hepatic CYP3A. Biochem Pharmacol.
filtration rate using aminoglycoside clearance in critically ill 1992;44:275.
medical patients. Ann Pharmacother. 1992;26:1205. 61. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES Jr, Weidler
41. Brater DC. Dosing regimens in renal disease. In: Jacobson HE, DJ. Relative bioavailability of ondansetron 8-mg oral tablets
Striker GA, Klahr S, eds. The Principles and Practice of versus two extemporaneous 16-mg suppositories: formulation
Nephrology. 2nd ed. St Louis, MO: Mosby-Year Book; 1995:15. and gender differneces. Pharmacotherapy. 1998;18:288.
42. Bennett WM, Aronoff GR, Golper TA, et al. Drug Prescribing in 62. Seaber E, On N, Dixon RM, et al. The absolute bioavailability
Renal Failure: Dosing Guidelines for Adults. 3rd ed. Philadelphia, and metabolic disposition of the novel antimigraine compound
PA: American College of Physicians; 1994:38. zolmitriptan (311C90). Br J Clin Pharmcol. 1997;43:579.
43. Swan SK, Bennett WM. Drug dosing guidelines in patients with 63. Loi CM, Parker BM, Cusack B, Vestal RE. Aging and drug
renal failure. West J Med. 1992;156:633. interactions. III. Individual and combined effects of cimetidine
44. Shuler C, Golper TA, Bennett WM. Prescribing drugs in renal and cimetidine and ciprofloxacin on theophylline metabolism
disease. In: Brenner BM, ed. The Kidney. 5th ed. Philadelphia, in helathy male and female nonsmokers. J Pharmacol Exp Ther.
PA:Saunders; 1996:51. 1997;280:627.
45. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and 64. Reigner BG, Welker HA. Factors influencing elimination and
transport in patients with kidney disease. Am J Kidney Dis. distribution of fleroxacin: metaanalysis of individual data from
2003;42:906-925. 10 pharmacokinetic studies. Antimicrob Agents Chemother.
1996;40:575.
46. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacoki-
netics in acute renal failure: preservation of nonrenal clearance. 65. Schwartz JB, Capili H, Daugherty J. Aging of women alters
Clin Pharmacol Ther. 1991;50:688. S-verapamil pharmacokinetics and pharmacodynamics. Clin
Pharmacol Ther. 1994;55:509.
47. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem
pharmacokinetics in patients with acute or chronic renal fail- 66. Lennard MS. Genetically determined adverse drug reactions
ure treated with continuous hemofiltration. Am J Kidney Dis. involving metabolism. Drug Safety. 1993;9:60.
1993;21:172. 67. Tucker GT. Clinical implications of genetic polymorphism in
48. Wrighton SA, Stevens JC. The human hepatic cytochromes drug metabolism. J Pharm Pharmacol. 1994;46(suppl 1):417.
p450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1. 68. Vessel ES. Therapeutic lessons from pharmacogenetics. Ann
49. Tukey RH, Johnson EF. Molecular aspects of regulation and Intern Med. 1997;126:653.
structures of the drug-metabolizing enzymes. In: Pratt WB, 69. Nebert DW, Weber WW. Pharmacogenetics. In Pratt WB,
Taylor P, eds. Principles of Drug Action. 3rd ed. New York: Taylor P eds. Principles of Drug Action. 3rd ed. New York:
Churchill Livingstone; 1990:56. Churchill Livingstone; 1990:60.

Section11-O-Ref.indd 2 12/10/2014 8:08:26 PM